compounding semaglutide fda enforcement news today The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the FDA alerts health care providers,

Based on Lilly's precedent with tirzepatide, retatrutide will likely receive separate brand names for different indications: Tirzepatide became Mounjaro for type 2 diabetes and Zepbound for obesity Retatrutide is expected to follow the same pattern with distinct brand names per indication Brand names are typically announced closer to the FDA approval date or during the NDA review period

If you're still losing, it's working

Do you see period and cycle tracking apps becoming a standard part of monitoring hormonal health in patients taking new medications

Retatrutide vs CagriSema: Next-Gen Weight Loss Medications Compared 28.7% vs 20.4%: Triple agonist meets dual combination in the race for obesity dominance Introduction Two medications are racing toward FDA approval with weight loss results that surpass anything currently available